Urs Meyer1, Joram Feldon. 1. Laboratory of Behavioral Neurobiology, ETH Zurich, Schorenstrasse 16, Schwerzenbach, Switzerland. urmeyer@ethz.ch
Abstract
RATIONALE: Prenatal exposure to infection is a notable environmental risk factor in the development of schizophrenia. One prevalent hypothesis suggests that infection-induced disruption of early prenatal brain development predisposes the organism to long-lasting structural and functional brain abnormalities. Many of the prenatal infection-induced functional brain abnormalities appear to be closely associated with imbalances in the mesocorticolimbic dopamine system in adult life, suggesting that disruption of functional and structural dopaminergic development may be at the core of the developmental neuropathology associated with psychosis-related abnormalities induced by prenatal exposure to infection. OBJECTIVES: In this review, we integrate recent findings derived from experimental models in animals with parallel research in humans which supports this hypothesis. We thereby highlight the developmental perspective of abnormal DA functions following in-utero exposure to infection in relation to the developmental and maturational mechanisms potentially involved in schizophrenia. RESULTS: Experimental investigations show that early prenatal immune challenge can lead to the emergence of early structural and functional alterations in the mesocorticolimbic DA system, long before the onset of the full spectrum of psychosis-associated behavioral and cognitive abnormalities in adulthood. CONCLUSIONS: Dopaminergic mal-development in general, and following prenatal immune activation in particular, may represent a primary etiopathological mechanism in the development of schizophrenia and related disorders. This hypothesis differs from the view that dopaminergic abnormalities in schizophrenia may be secondary to abnormalities in other brain structures and/or neurotransmitter systems. The existence of primary dopaminergic mechanisms may have important implications for the identification and early treatment of individuals prodromally symptomatic for schizophrenia.
RATIONALE: Prenatal exposure to infection is a notable environmental risk factor in the development of schizophrenia. One prevalent hypothesis suggests that infection-induced disruption of early prenatal brain development predisposes the organism to long-lasting structural and functional brain abnormalities. Many of the prenatal infection-induced functional brain abnormalities appear to be closely associated with imbalances in the mesocorticolimbic dopamine system in adult life, suggesting that disruption of functional and structural dopaminergic development may be at the core of the developmental neuropathology associated with psychosis-related abnormalities induced by prenatal exposure to infection. OBJECTIVES: In this review, we integrate recent findings derived from experimental models in animals with parallel research in humans which supports this hypothesis. We thereby highlight the developmental perspective of abnormal DA functions following in-utero exposure to infection in relation to the developmental and maturational mechanisms potentially involved in schizophrenia. RESULTS: Experimental investigations show that early prenatal immune challenge can lead to the emergence of early structural and functional alterations in the mesocorticolimbic DA system, long before the onset of the full spectrum of psychosis-associated behavioral and cognitive abnormalities in adulthood. CONCLUSIONS: Dopaminergic mal-development in general, and following prenatal immune activation in particular, may represent a primary etiopathological mechanism in the development of schizophrenia and related disorders. This hypothesis differs from the view that dopaminergic abnormalities in schizophrenia may be secondary to abnormalities in other brain structures and/or neurotransmitter systems. The existence of primary dopaminergic mechanisms may have important implications for the identification and early treatment of individuals prodromally symptomatic for schizophrenia.
Authors: M Toru; S Watanabe; H Shibuya; T Nishikawa; K Noda; H Mitsushio; H Ichikawa; A Kurumaji; M Takashima; N Mataga Journal: Acta Psychiatr Scand Date: 1988-08 Impact factor: 6.392
Authors: Y Okubo; T Suhara; K Suzuki; K Kobayashi; O Inoue; O Terasaki; Y Someya; T Sassa; Y Sudo; E Matsushima; M Iyo; Y Tateno; M Toru Journal: Nature Date: 1997-02-13 Impact factor: 49.962
Authors: Christoph Kellendonk; Eleanor H Simpson; H Jonathan Polan; Gaël Malleret; Svetlana Vronskaya; Vanessa Winiger; Holly Moore; Eric R Kandel Journal: Neuron Date: 2006-02-16 Impact factor: 17.173
Authors: José L Moreno; Mitsumasa Kurita; Terrell Holloway; Javier López; Richard Cadagan; Luis Martínez-Sobrido; Adolfo García-Sastre; Javier González-Maeso Journal: J Neurosci Date: 2011-02-02 Impact factor: 6.167
Authors: Charles V Vorhees; Devon L Graham; Amanda A Braun; Tori L Schaefer; Matthew R Skelton; Neil M Richtand; Michael T Williams Journal: Synapse Date: 2012-05-15 Impact factor: 2.562
Authors: Melissa D Bauman; Ana-Maria Iosif; Stephen E P Smith; Catherine Bregere; David G Amaral; Paul H Patterson Journal: Biol Psychiatry Date: 2013-09-05 Impact factor: 13.382
Authors: Sina Hafizi; Huai-Hsuan Tseng; Naren Rao; Thiviya Selvanathan; Miran Kenk; Richard P Bazinet; Ivonne Suridjan; Alan A Wilson; Jeffrey H Meyer; Gary Remington; Sylvain Houle; Pablo M Rusjan; Romina Mizrahi Journal: Am J Psychiatry Date: 2016-09-09 Impact factor: 18.112
Authors: Marisa Möller; Jan L Du Preez; Francois P Viljoen; Michael Berk; Brian H Harvey Journal: Metab Brain Dis Date: 2013-09-03 Impact factor: 3.584
Authors: Sarah E Canetta; Yuanyuan Bao; Mary Dawn T Co; Francis A Ennis; John Cruz; Masanori Terajima; Ling Shen; Christoph Kellendonk; Catherine A Schaefer; Alan S Brown Journal: Am J Psychiatry Date: 2014-05 Impact factor: 18.112
Authors: Nicolas Petitdant; Anthony Lecomte; Franck Robidel; Christelle Gamez; Kelly Blazy; Anne-Sophie Villégier Journal: Environ Sci Pollut Res Int Date: 2018-02-03 Impact factor: 4.223